Valeant Pharmaceuticals entered into an agreement to sell iNova Pharmaceuticals to a company owned by Pacific Equity Partners and The Carlyle Group for $930 million.
Here's what you should know:
1. Valeant CEO Joseph Papa said in a release Valeant made the sale to "strengthen our balance sheet."
2. iNova sold prescription and over-the-counter products for weight management, pain management, cardiology as well as cough and cold medicine.
3. Valeant will continue to sell in markets where iNova is present through its Bausch + Lomb franchise.
4. Valeant will use the $930 million to pay off term loan debt under its senior secured credit facility.
More articles on improving health:
Wisconsin health system expand services through new clinic, provider — 3 insights
XBiotech discontinues phase III study for colorectal cancer antibody therapy — 4 insights
Gastroenterologists ignoring H.pylori guidelines, survey says — 3 insights